VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Tuesday, January 6, 2026
Stock Comparison
Bristol-Myers Squibb Company vs TMX Group Limited
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
Bristol-Myers Squibb Company
BMY · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Bristol-Myers Squibb Company's moat claims, evidence, and risks.
View BMY analysisTMX Group Limited
X · Toronto Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into TMX Group Limited's moat claims, evidence, and risks.
View X analysisComparison highlights
- Moat score gap: TMX Group Limited leads (70 / 100 vs 56 / 100 for Bristol-Myers Squibb Company).
- Segment focus: Bristol-Myers Squibb Company has 5 segments (27.6% in Eliquis franchise (apixaban)); TMX Group Limited has 9 segments (16.1% in Trayport energy trading workflow software and network).
- Moat breadth: Bristol-Myers Squibb Company has 4 moat types across 3 domains; TMX Group Limited has 12 across 5.
Primary market context
Bristol-Myers Squibb Company
Eliquis franchise (apixaban)
Direct oral anticoagulants (DOACs) for stroke prevention in NVAF and treatment/prevention of DVT/PE
Global
Payers, PBMs, hospitals, clinics, pharmacies
Branded drug manufacturer (co-commercialization alliance)
27.6%
TMX Group Limited
Trayport energy trading workflow software and network
Wholesale energy trading workflow software and network connectivity
Europe-centric, with global customers
Energy traders, brokers, exchanges/venues
Interoperability hub / workflow platform
16.1%
Side-by-side metrics
Moat coverage
Shared moat types
Bristol-Myers Squibb Company strengths
TMX Group Limited strengths
Segment mix
Bristol-Myers Squibb Company segments
Full profile >Eliquis franchise (apixaban)
Oligopoly
Immuno-oncology checkpoint inhibitors (Opdivo/Yervoy/Opdualag)
Oligopoly
Hematology (Revlimid/Pomalyst/Reblozyl)
Competitive
Immunology (Orencia/Sotyktu)
Competitive
Other specialty & emerging products (CAR-T, cardiomyopathy, neuroscience, and mature brands)
Competitive
TMX Group Limited segments
Full profile >TSX & TSXV listing and sustaining fees
Oligopoly
Issuer services (TSX Trust and TMX Newsfile)
Competitive
Equities and fixed income trading venues (TSX, TSXV, TSX Alpha, Shorcan)
Oligopoly
Post-trade clearing, settlement and depository (CDS / CDSX)
Quasi-Monopoly
Canadian listed derivatives trading and clearing (Montreal Exchange + CDCC, excl. BOX)
Quasi-Monopoly
U.S. equity options exchange (BOX)
Competitive
Trayport energy trading workflow software and network
Oligopoly
TMX Datalinx market data and co-location
Quasi-Monopoly
TMX VettaFi indexing, ETF analytics, and digital distribution
Oligopoly
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listLooking for expansion-stage stocks?
Proven models entering the expansion stage with unit economics that work.
View expansion-stage stocksCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.